Karolinska Development AB announced that its portfolio company Modus Therapeutics has completed the recruitment in a clinical phase 1b study of sevuparin, where the company's lead asset sevuparin is being evaluated for the treatment of sepsis and septic shock. The randomized, placebo-controlled phase 1b study evaluates the effects of sevuparin in healthy volunteers after they have been induced with the bacterial toxin lipopolysaccharide (LPS), a provocation that is a well-established model for characterizing early stages of septic inflammation. The aim of the study is also to evaluate the safety profile of sevuparin when the substance is used in combination with heparin, a standard prophylactic, blood-thinning substance.

The results from the phase 1b study are expected to be communicated in the fourth quarter of 2022. Karolinska Development's direct ownership interest, and indirect ownership interest via KDev Investment, in Modus Therapeutics amounts to 38% and 17%, respectively.